Ebola virus disease
|Ebola virus disease|
|Classification and external resources|
Ebola virus disease (EVD; also Ebola hemorrhagic fever (EHF)) or simply Ebola is a disease of humans and other primates caused by ebolaviruses. Signs and symptoms typically start between two days and three weeks after contracting the virus, with a fever, sore throat, muscle pain and headaches. Then, vomiting, diarrhea and rash usually follows, along with decreased function of the liver and kidneys. At this time, generally, some people begin to bleed both internally and externally. Death, if it occurs, is typically six to sixteen days after symptoms appear and is often due to low blood pressure from fluid loss.
The virus is acquired by contact with blood or other body fluids of an infected human or other animal. This may also occur by direct contact with a recently contaminated item. Spread through the air has not been documented in the natural environment. Fruit bats are believed to be the normal carrier in nature, able to spread the virus without being affected. Humans become infected by contact with the bats or a living or dead animal that has been infected by bats. Once human infection occurs, the disease may spread between people as well. Male survivors may be able to transmit the disease via semen for nearly two months. To diagnose EVD, other diseases with similar symptoms such as malaria, cholera and other viral hemorrhagic fevers are first excluded. Blood samples are tested for viral antibodies, viral RNA, or the virus itself to confirm the diagnosis.
Outbreak control requires a coordinated series of medical services, along with a certain level of community engagement. The necessary medical services include rapid detection and contact tracing, quick access to appropriate laboratory services, proper management of those who are infected, and proper disposal of the dead through cremation or burial. Prevention includes decreasing the spread of disease from infected animals to humans. This may be done by only handling potentially infected bush meat while wearing protective clothing and by thoroughly cooking it before consumption. It also includes wearing proper protective clothing and washing hands when around a person with the disease. Samples of body fluids and tissues from people with the disease should be handled with special caution.
No specific treatment for the disease is yet available. Efforts to help those who are infected are supportive and include giving either oral rehydration therapy (slightly sweetened and salty water to drink) or intravenous fluids. This supportive care improves outcomes. The disease has a high risk of death, killing between 25% and 90% of those infected with the virus, averaging out at 50%. EVD was first identified in an area of Sudan (now part of South Sudan), as well as in Zaire (now the Democratic Republic of the Congo). The disease typically occurs in outbreaks in tropical regions of sub-Saharan Africa. From 1976 (when it was first identified) through 2013, the World Health Organization reported a total of 1,716 cases. The largest outbreak to date is the ongoing 2014 West African Ebola outbreak, which is currently affecting Guinea, Sierra Leone, and Liberia. As of 22 October 2014[update], 9,911 suspected cases resulting in the deaths of 4,868 have been reported. Efforts are under way to develop a vaccine.
- 1 Signs and symptoms
- 2 Cause
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Treatment
- 7 Prognosis
- 8 Epidemiology
- 9 Society and culture
- 10 Other animals
- 11 Research
- 12 See also
- 13 References
- 14 External links
Signs and symptoms
The time between exposure to the virus and the development of symptoms of the disease is usually 2 to 21 days. Estimates based on mathematical models predict that around 5% of cases may take greater than 21 days to develop.
Symptoms usually begin with a sudden influenza-like stage characterized by feeling tired, fever, pain in the muscles and joints, headache, and sore throat. The fever is usually greater than 38.3 °C (100.9 °F). This is often followed by: vomiting, diarrhea and abdominal pain. Shortness of breath and chest pain may occur next along with swelling, headaches and confusion. In about half of cases the skin may develop a maculopapular rash (a flat red area covered with small bumps).
In some cases, internal and external bleeding may occur. This typically begins five to seven days after first symptoms. All people show some decreased blood clotting. Bleeding from mucous membranes or from sites of needle punctures is reported in 40–50% of cases. This may result in the vomiting of blood, coughing up of blood or blood in stool. Bleeding into the skin may create petechiae, purpura, ecchymoses, hematomas (especially around needle injection sites). There may also be bleeding into the whites of the eyes. Heavy bleeding is uncommon and if it occurs is usually within the gastrointestinal tract.
Recovery may begin between 7 and 14 days after the start of symptoms. Death, if it occurs, is typically 6 to 16 days from the start of symptoms and is often due to low blood pressure from fluid loss. In general, the development of bleeding often indicates a worse outcome and this blood loss can result in death. People are often in a coma near the end of life. Those who survive often have ongoing muscle and joint pain, liver inflammation, and decreased hearing among other difficulties.
Ebola virus disease in humans is caused by four of five viruses in the genus Ebolavirus. The four are Bundibugyo virus (BDBV), Sudan virus (SUDV), Taï Forest virus (TAFV), and one called, simply, Ebola virus (EBOV, formerly Zaire Ebola virus). Ebola virus is the only member of the Zaire ebolavirus species and the most dangerous of the known EVD-causing viruses, as well as being responsible for the largest number of outbreaks. The fifth virus, Reston virus (RESTV), is not thought to cause disease in humans, but has caused disease in other primates. These five viruses are closely related to marburgviruses.
The spread of Ebola between people occurs only by direct contact with the blood or body fluids of a person after symptoms have developed. Body fluids that may contain ebolaviruses include saliva, mucus, vomit, feces, sweat, tears, breast milk, urine, and semen. Entry points include the nose, mouth, eyes, or open wounds, cuts and abrasions. Contact with objects contaminated by the virus, particularly needles and syringes may also transmit the infection. The virus is able to survive on objects for a few hours in a dried state and can survive for a few days within body fluids. Ebola virus may be able to persist in the semen of survivors for up to seven weeks after recovery, which could give rise to infections via sexual intercourse. Otherwise, people who have recovered are not infectious. The potential for widespread infections in countries with medical systems capable of observing correct medical isolation procedures is considered low. Usually when someone has symptoms, they are sufficiently unwell that they are unable to travel without assistance.
Handling infected dead bodies is a risk, including embalming. Because dead bodies are still infectious, traditional burial rituals may spread the disease. Nearly two thirds of the cases of Ebola infections in Guinea during the 2014 outbreak are believed to have been contracted via unprotected (or unsuitably protected) contact with infected corpses during certain Guinean burial rituals.
Healthcare workers treating those who are infected are at greatest risk of disease. This occurs when they do not wear appropriate protective clothing such as masks, gowns, gloves and eye protection. This is particularly common in parts of Africa where the health systems function poorly and where the disease mostly occurs. Hospital-acquired transmission has also occurred in African countries due to the reuse of needles. Some healthcare centers caring for people with the disease do not have running water. In the United States, spread has occurred due to inadequate isolation.
Airborne transmission has not been documented during EVD outbreaks. Transmission among rhesus monkeys via breathable 0.8–1.2 μm aerosolized droplets has been demonstrated in the laboratory. That airborne transmission does not appear to occur in humans may be due to there not being high enough levels of the virus in the lungs. Spread by water or food other than bushmeat has also not been observed, nor has spread by mosquitos or other insects.
While it is not entirely clear how Ebola initially spreads from animals to human, it is believed to involve direct contact with an infected wild animal or fruit bat. Wild animals other than bats capable of being infected include: a number of monkey, chimpanzees, gorillas, baboons and duikers. In Africa wild animals, including fruit bats are hunted to eat, being known as bushmeat.
Animals may become infected when they eat fruit already partially eaten by bats carrying the virus. Fruit production, animal behavior, and other factors may trigger outbreaks among animal populations.
It does appear that both domestic dog and pigs can also be infected with ebola viruses. Dogs when they carry the virus do not appear to develop symptoms, while pigs appear to be able to transmit the virus to at least some primates.
The natural reservoir for Ebola has yet to be confirmed; however, bats are considered to be the most likely candidate. Three types of fruit bats (Hypsignathus monstrosus, Epomops franqueti, and Myonycteris torquata) have been found to possibly carry the virus without getting sick. Whether or not other animals are involved in its spread is not known as of 2013. Plants, arthropods, and birds have also been considered as possible reservoirs as well.
Bats were known to reside in the cotton factory in which the first cases of the 1976 and 1979 outbreaks were observed, and they have also been implicated in Marburg virus infections in 1975 and 1980. Of 24 plant species and 19 vertebrate species experimentally inoculated with EBOV, only bats became infected. The bats displayed no clinical signs and is evidence that these bats are a reservoir species of the virus. In a 2002–2003 survey of 1,030 animals including 679 bats from Gabon and the Republic of the Congo, 13 fruit bats were found to contain EBOV RNA fragments. Antibodies against Zaire and Reston viruses have been found in fruit bats in Bangladesh, thus identifying potential virus hosts and signs of the filoviruses in Asia.
Between 1976 and 1998, in 30,000 mammals, birds, reptiles, amphibians and arthropods sampled from outbreak regions, no Ebola virus was detected apart from some genetic traces found in six rodents (Mus setulosus and Praomys) and one shrew (Sylvisorex ollula) collected from the Central African Republic. Further efforts; however, have not confirmed rodents as a reservoir. Traces of EBOV were detected in the carcasses of gorillas and chimpanzees during outbreaks in 2001 and 2003, which later became the source of human infections. However, the high lethality from infection in these species makes them unlikely as a natural reservoir.
Ebolaviruses contain single-strand, non-infectious RNA genomes. Ebolavirus genomes are approximately 19 kilobase pairs long and contain seven genes in the order 3'-UTR-NP-VP35-VP40-GP-VP30-VP24-L-5'-UTR. The genomes of the five different ebolaviruses (BDBV, EBOV, RESTV, SUDV, and TAFV) differ in sequence and the number and location of gene overlaps. Like all filoviruses, ebolavirions are filamentous particles that may appear in the shape of a shepherd's crook or in the shape of a "U" or a "6", and they may be coiled, toroid, or branched. In general, ebolavirions are 80 nanometers (nm) in width and may be as long as 14,000 nm. In general, the median particle length of ebolaviruses ranges from 974 to 1,086 nm (in contrast to marburgvirions, whose median particle length was measured at 795–828 nm), but particles as long as 14,000 nm have been detected in tissue culture.
Their life cycle begins with virion attachment to specific cell-surface receptors, followed by fusion of the virion envelope with cellular membranes and the concomitant release of the virus nucleocapsid into the cytosol. Ebolavirus' structural glycoprotein (known as GP1,2) is responsible for the virus' ability to bind to and infect targeted cells. The viral RNA polymerase, encoded by the L gene, partially uncoats the nucleocapsid and transcribes the genes into positive-strand mRNAs, which are then translated into structural and nonstructural proteins. The most abundant protein produced is the nucleoprotein, whose concentration in the cell determines when L switches from gene transcription to genome replication. Replication results in full-length, positive-strand antigenomes that are, in turn, transcribed into negative-strand virus progeny genome copy. Newly synthesized structural proteins and genomes self-assemble and accumulate near the inside of the cell membrane. Virions bud off from the cell, gaining their envelopes from the cellular membrane they bud from. The mature progeny particles then infect other cells to repeat the cycle. The Ebola virus genetics are difficult to study due to its virulent nature.
Cells lining the inside of blood vessels (endothelial cells), macrophages, monocytes, and liver cells are the main targets of infection. Macrophages are the first cells to be infected with the virus and this infection results in cellular death. Endothelial cells can be infected within three days after exposure to the virus. After infection, a secreted glycoprotein, known as small soluble glycoprotein (sGP) or as the Ebola virus glycoprotein (GP), is synthesized. Ebolavirus replication overwhelms protein synthesis of infected cells and host immune defenses. The GP forms a trimeric complex, which binds the virus to the endothelial cells. The sGP forms a dimeric protein that interferes with the signaling of neutrophils, a type of white blood cell, which allows the virus to evade the immune system by inhibiting early steps of neutrophil activation. These white blood cells also serve as carriers to transport the virus throughout the entire body to places such as the lymph nodes, liver, lungs, and spleen. The presence of viral particles and cell damage resulting from viruses budding out of the cell causes the release of chemical signals (such as TNF-α, IL-6, and IL-8), which are molecular signals for fever and inflammation. The damage to human cells, caused by infection of the endothelial cells, decreases blood vessel integrity. This loss of vascular integrity is furthered with the synthesis of GP, which reduces specific integrins responsible for cell adhesion to the intercellular structure, and damage to the liver, which leads to improper clotting.
Filoviral infection is also known to interfere with proper functioning of the innate immune system. Ebolavirus proteins blunt the human immune system's response to viral infections by interfering with cells' ability to produce and respond to interferon proteins such as interferon-alpha, interferon-beta, and interferon gamma. This interference is accomplished by the VP24 and VP35 ebolavirus structural proteins. When a cell is infected with ebolavirus, receptors located in the cell's cytosol (such as RIG-I and MDA5) or outside of the cytosol (such as Toll-like receptor 3, Toll-like receptor 7, Toll-like receptor 8, and Toll-like receptor 9), recognize infectious molecules associated with the virus. After these receptors are activated, proteins including interferon regulatory factor 3 and interferon regulatory factor 7 start a signaling cascade that leads to the expression of type 1 interferons. Type 1 interferons are then released and bind to the IFNAR1 and IFNAR2 receptors expressed on the surface of the neighboring cell. Once interferon has bound to its receptors on the neighboring cell, the signaling proteins STAT1 and STAT2 are activated and move to the cell's nucleus. This triggers the expression of interferon-stimulated genes, which code for proteins that have antiviral properties. Ebolavirus' V24 protein prevents the STAT1 signaling protein in the neighboring cell from entering the nucleus and therefore prevents the creation of these antiviral proteins. A separate ebolavirus protein, known as VP35, directly inhibits the production of interferon-beta. The ability to inhibit these immune responses creates an environment in which Ebolavirus can quickly spread throughout the body.
When the diagnosis of EVD is suspected, the travel and work history along with exposure to wildlife are important factors to consider. The diagnosis is confirmed by isolating the virus, detecting its RNA or proteins, or detecting antibodies against the virus in a person's blood. Isolating the virus by cell culture, detecting the viral RNA by polymerase chain reaction (PCR) and detecting proteins by enzyme-linked immunosorbent assay (ELISA) works best early and in those who have died from the disease. Detecting antibodies against the virus works best late in the disease and in those who recover.
During an outbreak, virus isolation is often not feasible. The most common diagnostic methods are therefore real-time PCR and ELISA detection of proteins, which can be performed in field or mobile hospitals. Filovirions can be seen and identified in cell culture by electron microscopy due to their unique filamentous shapes, but electron microscopy cannot tell the difference between the various filoviruses despite there being some length differences.
Changes on laboratory tests as a result of Ebola virus disease include a low platelet count in the blood, an initially decreased white blood cell count followed by an increase in the white blood cell count, elevated levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and abnormalities in clotting often consistent with disseminated intravascular coagulation (DIC) such as a prolonged prothrombin time, partial thromboplastin time, and bleeding time.
Early symptoms of EVD may be similar to those of other diseases common in Africa including malaria and dengue fever. The symptoms are also similar to those of Marburg virus disease and other viral hemorrhagic fevers.
The complete differential diagnosis is long and includes many other infectious diseases such as typhoid fever, shigellosis, rickettsial diseases, cholera, sepsis, borreliosis, EHEC enteritis, leptospirosis, scrub typhus, plague, Q fever, candidiasis, histoplasmosis, trypanosomiasis, visceral leishmaniasis, measles, and viral hepatitis among others. Non-infectious diseases that can be confused with EVD include acute promyelocytic leukemia, hemolytic uremic syndrome, snake envenomation, clotting factor deficiencies/platelet disorders, thrombotic thrombocytopenic purpura, hereditary hemorrhagic telangiectasia, Kawasaki disease, and warfarin poisoning among others.
Recommended measures for people caring for those infected with Ebola include the wearing of protective clothing including masks, gloves, gowns, and goggles. The CDC recommends that no skin be exposed. These same measures are recommended for those who may handle objects contaminated by the infected person's body fluids. The CDC in 2014 began recommending that all people receive education on the proper suit-up and removal of personal protective equipment and that someone should be watching each step of the procedure to make sure it is done correctly. In Sierra Leone, the typical training period for the use of such safety equipment lasts approximately 12 days.
The infected person should be in barrier-isolation from other people. All equipment, medical waste, patient waste, and surfaces that may have come into contact with body fluids require disinfection. During the 2014 outbreak kits were put together to help familes treat Ebola in their homes which includes protective clothing as well as chlorine powder and other cleaning supplies. Education of those who provide care in these techniques, and the provision of such barrier-separation supplies has been a priority of the Doctors Without Borders organization.
Ebolaviruses can be eliminated with heat (heating for 30 to 60 minutes at 60 °C or boiling for 5 minutes). To disinfect surfaces, some lipid solvents such as some alcohol-based products, detergents, sodium hypochlorite (bleach) or calcium hypochlorite (bleaching powder), and other suitable disinfectants at appropriate concentrations can be used.
Education of the general public of the risk factors for Ebola infection and of the protective measures individuals can take is recommended by the World Health Organization. These measures include avoiding direct contact with infected people and regular hand washing using soap and water.
Bushmeat, an important source of protein in the diet of some Africans, should be handled with appropriate protective clothing and thoroughly cooked before consumption. Some research suggests that an outbreak in the wild animals used for consumption may result in a corresponding human outbreak. Since 2003, such animal outbreaks have been monitored with the aim of predicting and preventing Ebola outbreaks in humans.
If a person with Ebola dies, direct contact with the body should be avoided. Certain burial rituals, which might have included making any kind of direct contact with a dead body, require reformulation such that they consistently maintain a proper protective barrier between the dead body and the living. It is recommended that the bodies of people who have died from Ebola be buried or cremated only with proper care. Social anthropologists may help find alternatives to traditional rules for burials.
Transportation crews are instructed to follow a certain isolation procedure should anyone exhibit symptoms resembling the Ebola virus disease. The World Health Organization as of Aug 14, 2014 does not consider travel bans to be useful in decreasing spread.
In laboratories where diagnostic testing is carried out, biosafety level 4-equivalent containment is required, since ebolaviruses are World Health Organization Risk Group 4 pathogens. Laboratory researchers must be properly trained in BSL-4 practices and wear proper personal protective equipment.
Quarantine, also known as enforced isolation, is usually effective in decreasing spread. Governments often quarantine areas where the disease is occurring or individuals who may transmit the disease outside of an initial area. In the United States, the law allows quarantine of those infected with ebolaviruses. During the 2014 outbreak, Liberia closed schools. On October 16, 2014, some schools were closed in Ohio and Texas as a precaution after one of two nurses who contracted Ebola (after caring for a person with Ebola) returned to the Cleveland area and may have been on the same plane as some students, teachers, and parents of students from those schools.
Contact tracing is regarded as important to contain an outbreak. It involves finding everyone who had close contact with infected individuals and watching for signs of illness for 21 days. If any of these contacts comes down with the disease, they should be isolated, tested, and treated. Then repeat the process by tracing the contacts' contacts.
No specific treatment is currently approved. However, survival is improved by early supportive care with rehydration and symptomatic treatment. Treatment is primarily supportive in nature. These measures may include management of pain, nausea, fever and anxiety, as well as rehydration via the oral or by intravenous route. Blood products such as packed red blood cells, platelets or fresh frozen plasma may also be used. Other regulators of coagulation have also been tried including heparin in an effort to prevent disseminated intravascular coagulation and clotting factors to decrease bleeding. Antimalarial medications and antibiotics are often used before the diagnosis is confirmed, though there is no evidence to suggest such treatment is in any way helpful. Interferon therapies have been tried as a form of treatment for EVD, but were found to be ineffective.
Intensive care is often used in the developed world. This may include maintaining blood volume and electrolytes (salts) balance as well as treating any bacterial infections that may develop. Dialysis may be needed for kidney failure while extracorporeal membrane oxygenation may be used for lung dysfunction.
The Food and Drug Administration (FDA) advises people to be careful of advertisements making unverified or fraudulent claims of benefits supposedly gained from various anti-Ebola products. The FDA has already sent out at least one letter of warning to a seller of colloidal silver who made unverified claims of Ebola related benefits, supposedly derived from the use of their products.
Ebola virus disease has a high risk of death in those infected which varies between 25 percent and 90 percent of those infected. As of September 2014[update], the average risk of death among those infected is 50%. The risk of death was 90% in the 2002–2003 Republic of the Congo outbreak. There are indications based on variations between countries that early and effective treatment of symptoms (e.g., supportive care to prevent dehydration) may reduce the risk of death.
If an infected person survives, recovery may be quick and complete. Prolonged cases are often complicated by the occurrence of long-term problems, such as inflammation of the testicles, joint pains, muscle pains, skin peeling, or hair loss. Eye symptoms, such as light sensitivity, excess tearing, iritis, iridocyclitis, choroiditis, and blindness have also been described.
The disease typically occurs in outbreaks in tropical regions of Sub-Saharan Africa. From 1976 (when it was first identified) through 2013, the World Health Organization reported 1,716 confirmed cases. The largest outbreak to date is the ongoing 2014 West Africa Ebola virus outbreak, which is affecting Guinea, Sierra Leone, Liberia and Nigeria. As of 22 October 2014[update], 9,911 suspected cases and 4,868 deaths had been reported;.
The first known outbreak of Ebola virus disease (EVD) was identified only after the fact, occurring between June and November 1976 in Nzara, South Sudan, (then part of Sudan) and was caused by Sudan virus (SUDV). The Sudan outbreak infected 284 people and killed 151. The first identifiable case in Sudan occurred on 27 June in a storekeeper in a cotton factory in Nzara, who was hospitalized on 30 June and died on 6 July. While the WHO medical staff involved in the Sudan outbreak were aware that they were dealing with a heretofore unknown disease, the actual "positive identification" process and the naming of the virus did not occur until some months later in the Democratic Republic of the Congo.
On 26 August 1976, a second outbreak of EVD began in Yambuku, Zaire, a small rural village in Mongala District in northern Democratic Republic of the Congo (then known as Zaire). This outbreak was caused by Ebola virus (EBOV), formerly designated Zaire ebolavirus, which is a different member of the genus Ebolavirus than in the first Sudan outbreak. The first person infected with the disease was village school headmaster Mabalo Lokela, who began displaying symptoms on August 26, 1976. Lokela had returned from a trip to Northern Zaire near the Central African Republic border, having visited the Ebola River between 12–22 August. He was originally believed to have malaria and was given quinine. However, his symptoms continued to worsen, and he was admitted to Yambuku Mission Hospital on September 5. Lokela died on September 8, fourteen days after he began displaying symptoms.
Soon after Lokela's death, others who had been in contact with him also died, and people in the village of Yambuku began to panic. This led the country's Minister of Health along with Zaire President Mobutu Sese Seko to declare the entire region, including Yambuku and the country's capital, Kinshasa, a quarantine zone. No one was permitted to enter or leave the area, with roads, waterways, and airfields placed under martial law. Schools, businesses and social organizations were closed. Researchers from the CDC, including Peter Piot, co-discoverer of Ebola, later arrived to assess the effects of the outbreak, observing that "the whole region was in panic." The outbreak lasted 26 days, with the quarantine lasting two weeks. Among the reasons that researchers speculated caused the disease to disappear, were the precautions taken by locals, the quarantine of the area, and possibly most important, the discontinuance of reusing needles by local nurses.
During this outbreak, Dr. Ngoy Mushola recorded the first clinical description of Ebola virus disease in Yambuku, where he wrote the following in his daily log: "The illness is characterized with a high temperature of about 39°C, hematemesis, diarrhea with blood, retrosternal abdominal pain, prostration with "heavy" articulations, and rapid evolution death after a mean of three days."
The virus responsible for the initial outbreak, first thought to be Marburg virus, was later identified as a new type of virus related to marburgviruses. Virus strain samples isolated from both outbreaks were named as the "Ebola virus" after the Ebola River, located near the originally identified viral outbreak site in Zaire. Reports conflict about who initially coined the name: either Karl Johnson of the American CDC team or Belgian researchers. Subsequently a number of other cases were reported, almost all centered on the Yambuku mission hospital or having close contact with another case. 318 cases and 280 deaths (a 88% fatality rate) occurred in the DRC. Although it was assumed that the two outbreaks were connected, scientists later realized that they were caused by two distinct ebolaviruses, SUDV and EBOV. The Zaire outbreak was contained with the help of the World Health Organization and transport from the Congolese air force, by quarantining villagers, sterilizing medical equipment, and providing protective clothing.
1995 to 2013
The second major outbreak occurred in 1995 in the Democratic Republic of Congo, affecting 315 and killing 254. The next major outbreak occurred in Uganda in 2000, affecting 425 and killing 224; in this case the Sudan virus was found to be the ebolavirus species responsible for the outbreak. In 2003 there was an outbreak in the Republic of Congo that affected 143 and killed 128, a death rate of 90%, the highest to date.
In 2004 a Russian scientist died from Ebola after sticking herself with an infected needle.
In August 2007, 103 people were infected by a suspected hemorrhagic fever outbreak in the village of Kampungu, Democratic Republic of the Congo. The outbreak started after the funerals of two village chiefs, and 217 people in four villages fell ill. The 2007 outbreak eventually affected 264 individuals and resulted in the deaths of 187.
On 30 November 2007, the Uganda Ministry of Health confirmed an outbreak of Ebola in the Bundibugyo District in Western Uganda. After confirmation of samples tested by the United States National Reference Laboratories and the Centers for Disease Control, the World Health Organization confirmed the presence of a new species of Ebolavirus, which was tentatively named Bundibugyo. The WHO reported 149 cases of this new strain and 37 of those led to deaths.
The WHO confirmed two small outbreaks in Uganda in 2012. The first outbreak affected 7 people and resulted in the death of 4 and the second affected 24, resulting in the death of 17. The Sudan variant was responsible for both outbreaks.
On 17 August 2012, the Ministry of Health of the Democratic Republic of the Congo reported an outbreak of the Ebola-Bundibugyo variant in the eastern region. Other than its discovery in 2007, this was the only time that this variant has been identified as the ebolavirus responsible for an outbreak. The WHO revealed that the virus had sickened 57 people and claimed 29 lives. The probable cause of the outbreak was tainted bush meat hunted by local villagers around the towns of Isiro and Viadana.
2014 West African outbreak
In March 2014, the World Health Organization (WHO) reported a major Ebola outbreak in Guinea, a western African nation. Researchers traced the outbreak to a two-year old child who died on 28 December 2013. The disease then rapidly spread to the neighboring countries of Liberia and Sierra Leone. It is the largest Ebola outbreak ever documented, and the first recorded in the region.
On 8 August 2014, the WHO declared the epidemic to be an international public health emergency. Urging the world to offer aid to the affected regions, the Director-General said, "Countries affected to date simply do not have the capacity to manage an outbreak of this size and complexity on their own. I urge the international community to provide this support on the most urgent basis possible." By mid-August 2014, Doctors Without Borders reported the situation in Liberia's capital Monrovia as "catastrophic" and "deteriorating daily". They reported that fears of Ebola among staff members and patients had shut down much of the city’s health system, leaving many people without treatment for other conditions. By late August 2014, the disease had spread to Nigeria, and one case was reported in Senegal.  On 30 September 2014, the first confirmed case of Ebola in the United States was diagnosed. The patient died eight days later.
Aside from the human cost, the outbreak has severely eroded the economies of the affected countries. A Financial Times report suggested the economic impact of the outbreak could kill more people than the virus itself. As of 23 September, in the three hardest hit countries, Liberia, Sierra Leone, and Guinea, there were only 893 treatment beds available while the current need was 2122. In a 26 September statement, the WHO said, "The Ebola epidemic ravaging parts of West Africa is the most severe acute public health emergency seen in modern times. Never before in recorded history has a biosafety level four pathogen infected so many people so quickly, over such a broad geographical area, for so long."
As of 22 October 2014[update], 9,911 suspected cases and 4,868 deaths had been reported; however, the World Health Organization has said that these numbers may be vastly underestimated. The WHO reports that more than 216 healthcare workers are among the dead, partly due to the lack of equipment and long hours.
2014 spread outside of Africa
As of 15 October 2014, there have been 17 cases of Ebola treated outside of Africa, four of whom have died. In early October, Teresa Romero, a 44-year-old Spanish nurse, contracted Ebola after caring for a priest who had been repatriated from west Africa. This was the first transmission of the virus to occur outside of Africa.
On 19 September, Eric Duncan flew from his native Liberia to Texas; five days later he began showing symptoms and visited a hospital, but was sent home. His condition worsened and he returned to the hospital on 28 September, where he passed away on 8 October. Health officials confirmed a diagnosis of Ebola on 30 September—the first case in the United States. On 12 October, the CDC confirmed that a nurse in Texas who had treated Duncan was found to be positive for the Ebola virus, the first known case of the disease to be contracted in the United States. On 15 October, a second Texas healthcare worker was confirmed to have the virus.
Society and culture
Ebolavirus is classified as a biosafety level 4 agent, as well as a Category A bioterrorism agent by the Centers for Disease Control and Prevention. It has the potential to be weaponized for use in biological warfare, and was investigated by the Biopreparat for such use, but might be difficult to prepare as a weapon of mass destruction because the virus becomes ineffective quickly in open air.
Tom Clancy's 1996 novel, Executive Orders, involves a Middle Eastern terrorist attack on the United States using an airborne form of a deadly Ebola virus strain named "Ebola Mayinga" (see Mayinga N'Seka).
Clem Chambers’ 2012 thriller, The First Horseman, has bioterrorism using the Ebola virus as its pivotal theme. The premise is that an infected lab rat is fed live to modified mosquitoes, which are then released in the target area. 
Ebola has a high mortality among primates. Frequent outbreaks of Ebola may have resulted in the deaths of 5,000 gorillas. Outbreaks of Ebola may have been responsible for an 88% decline in tracking indices of observed chimpanzee populations in 420 square kilometer Lossi Sanctuary between 2002 and 2003. Transmission among chimpanzees through meat consumption constitutes a significant risk factor, while contact between the animals, such as touching dead bodies and grooming, is not.
Recovered carcasses from gorillas contain multiple Ebola virus strains, which suggest multiple introductions of the virus. Bodies decompose quickly and carcasses are not infectious after three to four days. Contact between gorilla groups is rare, suggesting transmission among gorilla groups is unlikely, and that outbreaks result from transmission between viral reservoir and animal populations.
In late 1989, Hazelton Research Products' Reston Quarantine Unit in Reston, Virginia, suffered a mysterious outbreak of fatal illness amongst certain lab monkeys. This lab outbreak was initially diagnosed as Simian hemorrhagic fever virus (SHFV), and occurred amongst a shipment of crab-eating macaque monkeys imported from the Philippines.
Hazelton's veterinary pathologist sent tissue samples from dead animals to the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Maryland, where an ELISA test indicated the antibodies present in the tissue were a response to ebola virus and not SHFV. An electron microscopist from USAMRIID discovered filoviruses similar in appearance to Ebola in the tissue samples sent from Hazelton Research Products' Reston Quarantine Unit.
Shortly afterward, a US Army team headquartered at USAMRIID went into action to euthanize the monkeys which had not yet died, bringing those monkeys and those which had already died of the disease to Ft. Detrick for study by the Army's veterinary pathologists and virologists, and eventual disposal under safe conditions.
Blood samples were taken from 178 animal handlers during the incident. Of those, six animal handlers eventually seroconverted, including one who had cut himself with a bloody scalpel. Despite its status as a Level‑4 organism and its apparent pathogenicity in monkeys, when the handlers did not become ill, the CDC concluded that the virus had a very low pathogenicity to humans.
The Philippines and the United States had no previous cases of Ebola infection, and upon further isolation, researchers concluded it was another strain of Ebola, or a new filovirus of Asian origin, which they named Reston ebolavirus (RESTV) after the location of the incident.
Reston virus (RESTV) can be transmitted to pigs.
In 2012 it was demonstrated that the virus can travel without contact from pigs to nonhuman primates, although the same study failed to achieve transmission in that manner between primates. According to the WHO, routine cleaning and disinfection of pig (or monkey) farms with sodium hypochlorite or other detergents should be effective in inactivating the Reston ebolavirus. If an outbreak is suspected, the area must be immediately quarantined.
While pigs that have been infected with RESTV tend to show symptoms of the disease, it has been shown that dogs may become infected with EBOV and remain asymptomatic. Dogs in some parts of Africa scavenge for their food and it is known that they sometimes eat infected animals and the corpses of humans. Although they remain asymptomatic, a 2005 survey of dogs during an EBOV outbreak found that over 31.8% showed a seroprevalence for EBOV closest to an outbreak versus 9% a farther distance away.
A number of experimental treatments are being studied. In the United States, the Food and Drug Administration (FDA)'s animal efficacy rule is being used to demonstrate reasonable safety to obtain permission to treat people who are infected with Ebola. It is being used because the normal path for testing drugs is not possible for diseases caused by dangerous pathogens or toxins. Experimental drugs are made available for use with the approval of regulatory agencies under named patient programs, known in the US as "expanded access". On 12 August 2014 the WHO released a statement that the use of not yet proven treatments is ethical in certain situations in an effort to treat or prevent the disease.
A number of antiviral medications are being studied.
- Favipiravir, an anti-viral drug approved in Japan for stockpiling against influenza pandemics, appears to be useful in a mouse model of Ebola. On 4 October 2014, it was reported that a French nun who contracted Ebola while volunteering in Liberia was cured with Favipiravir treatment.
- BCX4430 is a broad-spectrum small molecule antiviral drug developed by BioCryst Pharmaceuticals and undergoing animal testing as a potential human treatment for Ebola by USAMRIID. The drug has been approved to progress to Phase 1 trials, expected late in 2014.
- Brincidofovir is a broad-spectrum antiviral drug. Its maker has been granted FDA approval to proceed with a trial to test its safety and effectiveness in Ebola patients. It has been used to treat the first patient diagnosed with Ebola in the USA, after he had recently returned from Liberia.
- Lamivudine, an antiviral drug which is usually used to treat HIV / AIDS, was reported in September 2014 to have been used successfully to treat 13 out of 15 Ebola-infected patients by a doctor in Liberia, as part of a combination therapy also involving intravenous fluids and antibiotics to combat opportunistic bacterial infection of Ebola-compromised internal organs. Western virologists have however expressed caution about the results, due to the small number of patients treated and confounding factors present. Researchers at the NIH stated that lamivudine had so far failed to demonstrate anti-Ebola activity in preliminary in vitro tests, but that they would continue to test it under different conditions and would progress it to trials if even slight evidence for efficacy is found.
- JK-05 is an antiviral drug developed by the Chinese company Sihuan Pharmaceutical along with the Chinese Academy of Military Medical Sciences. It is reportedly being fast tracked through human trials for Ebola treatment after successful tests in mice.
- Lack of available treatment options has spurred research into a number of other possible antivirals targeted against Ebola, including natural products such as scytovirin and griffithsin, as well as synthetic drugs including FGI-103, FGI-104, FGI-106, dUY11 and LJ-001, and other newer agents.
Other promising treatments rely on antisense technology. Both small interfering RNAs (siRNAs) and phosphorodiamidate morpholino oligomers (PMOs) targeting Ebola virus (EBOV) RNA polymerase L protein may prevent disease in nonhuman primates. TKM-Ebola is a small interfering RNA compound, currently being tested in a Phase I clinical trial in humans. Sarepta Therapeutics has completed a Phase I clinical trial with its PMO protecting up to 80-100 percent of the non-human primates tested.
ZMapp is a monoclonal antibody vaccine. The limited supply of the drug has been used to treat a small number of individuals infected with the Ebola virus. Although some individuals have recovered, the outcome is not considered statistically significant. ZMapp has proved effective in a trial involving Rhesus macaque monkeys.
Researchers in Thailand claim to have developed an antibody-based treatment for Ebola using synthesized fragments of the virus. It has not been tested against Ebola itself. Scientists from the WHO and NIH have offered to test the treatment against live Ebola virus, but there is still a great deal of development needed before human trials.
Two selective estrogen receptor modulators usually used to treat infertility and breast cancer (clomiphene and toremifene) have been found to inhibit the progress of Ebola virus in vitro as well as in infected mice. Ninety percent of the mice treated with clomiphene and fifty percent of those treated with toremifene survived the tests. The study authors conclude that given their oral availability and history of human use, these drugs would be candidates for treating Ebola virus infection in remote geographical locations, either on their own or together with other antiviral drugs.
The WHO has stated that transfusion of whole blood or purified serum from Ebola survivors is the therapy with the greatest potential to be implemented immediately, although there is little information as to its efficacy. September 2014, WHO issued an interim guideline for this therapy. The blood serum from those who have survived an infection is currently being studied to see if it is an effective treatment. During a meeting arranged by WHO this research was deemed to be a top priority. Seven of eight people with Ebola survived after receiving a transfusion of blood donated by individuals who had previously survived the infection in an 1999 outbreak in the Democratic Republic of the Congo. This treatment, however, was started late in the disease meaning they may have already been recovering on their own and the rest of their care was better than usual. Thus this potential treatment remains controversial. Intravenous antibodies appear to be protective in non-human primates who have been exposed to large doses of Ebola. The World Health Organization has approved the use of convalescent serum and whole blood products to treat people with Ebola.
Many Ebola vaccine candidates have been developed in the past decade, but as of October 2014, none had yet been approved by the United States Food and Drug Administration (FDA) for clinical use in humans. Several promising vaccine candidates have been shown to protect nonhuman primates (usually macaques) against lethal infection. These include replication-deficient adenovirus vectors, replication-competent vesicular stomatitis (VSV) and human parainfluenza (HPIV-3) vectors, and virus-like particle preparations. Conventional trials to study efficacy by exposure of humans to the pathogen after immunization are obviously not feasible in this case. For such situations, the FDA has established the “animal rule” allowing licensure to be approved on the basis of animal model studies that replicate human disease, combined with evidence of safety and a potentially potent immune response (antibodies in the blood) from humans given the vaccine. Phase I clinical trials involve the administration of the vaccine to healthy human subjects to evaluate the immune response, identify any side effects and determine the appropriate dosage.
In September 2014, two Phase I clinical trials began for the vaccine cAd3-EBO Z, which is based on an attenuated version of a chimpanzee adenovirus (cAd3) that has been genetically altered so that it is unable to replicate in humans. It was developed by NIAID in collaboration with Okairos, now a division of GlaxoSmithKline. For the trial designated VRC 20, twenty volunteers were recruited by the NIAID in Bethesda, Maryland, while three dose-specific groups of twenty volunteers each were recruited for trial EBL01 by University of Oxford, U.K.
A replication-competent vaccine based on the vesicular stomatitis virus, called VSV-EBOV, was developed by the Canadian National Microbiology Laboratory and licensed to the small company NewLink Genetics. With the strong support of the U.S. Defense Threat Reduction Agency, it started Phase I clinical trials on healthy human subjects on October 13, 2014 at the Walter Reed Army Institute of Research in Silver Spring, Md. Also in October, 2014, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) was recruiting healthy human volunteers for a "Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults". On October 20, the Public Health Agency of Canada began air shipment of 800 doses of the VSV-EBOV vaccine to the WHO in Geneva. This vaccine is intended to be used in Phase I clinical trials, to start in late October or early November. The WHO has recruited 250 volunteers ready to begin Phase I clinical trials in four locations: Switzerland, Germany, Gabon and Kenya. If results of this and following trials are positive, the deployment of this vaccine in environments such as West Africa would be facilitated by the expected requirement of only a single dose due to its ability to replicate in humans. Also, its effectiveness in nonhuman primates when administered even after exposure to the virus could help to protect health-care workers after a suspected exposure.
The Health Ministry of Russia also claims to have developed a vaccine called Triazoverin, which is said to be effective against both Ebola and Marburg filoviruses, and might be available for clinical trials in West Africa as soon as the start of 2015.
- "Ebola virus disease Fact sheet N°103". World Health Organization. September 2014. Retrieved 12 April 2014.
- Ruzek, edited by Sunit K. Singh, Daniel (2014). Viral hemorrhagic fevers. Boca Raton: CRC Press, Taylor & Francis Group. p. 444. ISBN 9781439884294.
- "2014 Ebola Virus Disease (EVD) outbreak in West Africa". WHO. 21 April 2014. Retrieved 3 August 2014.
- "Guidance for Safe Handling of Human Remains of Ebola Patients in U. S. Hospitals and Mortuaries". Retrieved 10 October 2014.
- "Ebola Viral Disease Outbreak — West Africa, 2014". CDC. 27 June 2014. Retrieved 26 June 2014.
- "Guinea: Ebola Virus Disease (EVD) Outbreak". 17 October 2014. Retrieved 20 October 2014.
- "Sierra Leone: EBOLA VIRUS DISEASE - SITUATION REPORT (Sit-Rep) – 18 October, 2014". 17 October 2014. Retrieved 20 October 2014.
- "Liberia Ebola SitRep no. 155". 17 October 2014. Retrieved 20 October 2014.
- "CDC urges all US residents to avoid nonessential travel to Liberia, Guinea and Sierra Leone because of an unprecedented outbreak of Ebola.". CDC. 31 July 2014. Retrieved 2 August 2014.
- "Outbreak of Ebola in Guinea, Liberia and Sierra Leone". CDC. 4 August 2014. Retrieved 5 August 2014.
- "Ebola Hemorrhagic Fever Signs and Symptoms". CDC. 28 January 2014. Retrieved 2 August 2014.
- Charles N. Haas (October 14, 2014). "On the Quarantine Period for Ebola Virus". PLOS Currents Outbreaks. doi:10.1371/currents.outbreaks.2ab4b76ba7263ff0f084766e43abbd89.
- Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". J. Gen. Virol. 95 (Pt 8): 1619–1624. doi:10.1099/vir.0.067199-0. PMID 24795448.
- Magill, Alan (2013). Hunter's tropical medicine and emerging infectious diseases. (9th ed. ed.). New York: Saunders. p. 332. ISBN 9781416043904.
- Hoenen T, Groseth A, Falzarano D, Feldmann H (May 2006). "Ebola virus: unravelling pathogenesis to combat a deadly disease". Trends in Molecular Medicine 12 (5): 206–215. doi:10.1016/j.molmed.2006.03.006. PMID 16616875.
- Simpson DIH (1977). "Marburg and Ebola virus infections: a guide for their diagnosis, management, and control" (PDF). WHO Offset Publication No. 36. p. 10f.
- "Ebola Virus, Clinical Presentation". Medscape. Retrieved 30 July 2012.
- "Appendix A: Disease-Specific Chapters". Chapter: Hemorrhagic fevers caused by: i) Ebola virus and ii) Marburg virus and iii) Other viral causes including bunyaviruses, arenaviruses, and flaviviruses. Ministry of Health and Long-Term Care. Retrieved 9 October 2014.
- Feldmann H, Geisbert TW (5 March 2011). "Ebola haemorrhagic fever.". Lancet 377 (9768): 849–62. PMID 21084112.
- Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, Lloyd G, Simpson DI (1985). "Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola)". J. Infect. Dis. 152 (5): 887–894. doi:10.1093/infdis/152.5.887. PMID 4045253.
- Hoenen T, Groseth A, Feldmann H (July 2012). "Current ebola vaccines". Expert Opin Biol Ther 12 (7): 859–72. doi:10.1517/14712598.2012.685152. PMC 3422127. PMID 22559078.
- Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB (2010). "Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations". Archives of Virology 155 (12): 2083–103. doi:10.1007/s00705-010-0814-x. PMC 3074192. PMID 21046175.
- Spickler, Anna. "Ebolavirus and Marburgvirus Infections".
- "About Ebola Virus Disease". CDC. Retrieved 18 October 2014.
- "Q&A on Transmission, Ebola". CDC. September 2014. Retrieved 3 October 2014.
- "Transmission". CDC. October 17, 2014. Retrieved 18 October 2014.
- "CDC Telebriefing on Ebola outbreak in West Africa". CDC. 28 July 2014. Retrieved 3 August 2014.
- "Air travel is low-risk for Ebola transmission". WHO. 14 August 2014.
- Chan M (2014). "Ebola virus disease in West Africa—no early end to the outbreak". N. Engl. J. Med. 371 (13): 1183–5. doi:10.1056/NEJMp1409859. PMID 25140856.
- "Sierra Leone: a traditional healer and a funeral". World Health Organization. Retrieved 6 October 2014.
- Tiaji Salaam-Blyther (26 August 2014). "The 2014 Ebola Outbreak: International and U.S. Responses" (pdf). Retrieved 9 September 2014.
- Lashley, Felissa R.; Durham, Jerry D., eds. (2007). Emerging infectious diseases trends and issues (2nd ed.). New York: Springer. p. 141. ISBN 9780826103505.
- Alan J. Magill, G. Thomas Strickland, James H. Maguire, Edward T Ryan, Tom Solomon, ed. (2013). Hunter's tropical medicine and emerging infectious disease (9th ed.). London, New York: Elsevier. pp. 170–172. OCLC 822525408.
- "Questions and Answers on Ebola | Ebola Hemorrhagic Fever | CDC". CDC.
- "Ebola in Texas: Second Health Care Worker Tests Positive". October 15, 2014.
- Johnson E, Jaax N, White J, Jahrling P (August 1995). "Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus". International journal of experimental pathology 76 (4): 227–236. ISSN 0959-9673. PMC 1997182. PMID 7547435.
- Irving WL (Aug 1995). "Ebola virus transmission.". International journal of experimental pathology 76 (4): 225–6. PMID 7547434.
- Williams E. "African monkey meat that could be behind the next HIV". Health News - Health & Families. The Independent. "25 people in Bakaklion, Cameroon killed due to eating of ape"
- "EBOLAVIRUS". http://www.phac-aspc.gc.ca/. 2014-08-22. Retrieved 22 October 2014.
- "Risk of Exposure". CDC. October 12, 2014. Retrieved 18 October 2014.
- "FAO warns of fruit bat risk in West African Ebola epidemic". fao.org. 21 July 2014. Retrieved 22 October 2014.
- Gonzalez JP, Pourrut X, Leroy E (2007). "Wildlife and Emerging Zoonotic Diseases: The Biology, Circumstances and Consequences of Cross-Species Transmission". Current Topics in Microbiology and Immunology. Ebolavirus and other filoviruses 315: 363–387. doi:10.1007/978-3-540-70962-6_15. ISBN 978-3-540-70961-9. PMID 17848072.
- Weingartl, HM; Nfon, C; Kobinger, G (2013). "Review of Ebola virus infections in domestic animals.". Developments in biologicals 135: 211–8. PMID 23689899.
- "Questions and Answers about Ebola and Pets". CDC. 11 December 2005.
- Pourrut X, Délicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM (2007). "Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species". The Journal of infectious diseases. Suppl 2 (s2): S176–S183. doi:10.1086/520541. PMID 17940947.
- Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Délicat A, Yaba P, Nkoghe D, Gonzalez JP, Leroy EM (2005). "The natural history of Ebola virus in Africa". Microbes and infection / Institut Pasteur 7 (7–8): 1005–1014. doi:10.1016/j.micinf.2005.04.006. PMID 16002313.
- Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, Rollin PE, Zaki SR, Peters CJ (Oct 1996). "Experimental inoculation of plants and animals with Ebola virus". Emerging Infectious Diseases 2 (4): 321–325. doi:10.3201/eid0204.960407. ISSN 1080-6040. PMC 2639914. PMID 8969248.
- Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Délicat A, Paweska JT, Gonzalez JP, Swanepoel R (2005). "Fruit bats as reservoirs of Ebola virus". Nature 438 (7068): 575–576. Bibcode:2005Natur.438..575L. doi:10.1038/438575a. PMID 16319873.
- Olival KJ, Islam A, Yu M, Anthony SJ, Epstein JH, Khan SA, Khan SU, Crameri G, Wang LF, Lipkin WI, Luby SP, Daszak P (2013). "Ebola virus antibodies in fruit bats, bangladesh". Emerging Infect. Dis. 19 (2): 270–3. doi:10.3201/eid1902.120524. PMC 3559038. PMID 23343532.
- Morvan JM, Deubel V, Gounon P, Nakouné E, Barrière P, Murri S, Perpète O, Selekon B, Coudrier D, Gautier-Hion A, Colyn M, Volehkov V (1999). "Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic". Microbes and Infection 1 (14): 1193–1201. doi:10.1016/S1286-4579(99)00242-7. PMID 10580275.
- Groseth, A; Feldmann, H; Strong, JE (September 2007). "The ecology of Ebola virus.". Trends in microbiology 15 (9): 408–16. PMID 17698361.
- Pringle, C. R. (2005). "Order Mononegavirales". In Fauquet, C. M.; Mayo, M. A.; Maniloff, J.; Desselberger, U.; Ball, L. A. Virus Taxonomy – Eighth Report of the International Committee on Taxonomy of Viruses. San Diego, US: Elsevier/Academic Press. pp. 609–614. ISBN 0-12-370200-3.
- Kiley MP, Bowen ET, Eddy GA, Isaäcson M, Johnson KM, McCormick JB, Murphy FA, Pattyn SR, Peters D, Prozesky OW, Regnery RL, Simpson DI, Slenczka W, Sureau P, van der Groen G, Webb PA, Wulff H (1982). "Filoviridae: A taxonomic home for Marburg and Ebola viruses?". Intervirology 18 (1–2): 24–32. doi:10.1159/000149300. PMID 7118520.
- Chippaux JP (October 2014). "Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga". J Venom Anim Toxins Incl Trop Dis 20 (1): 44. doi:10.1186/1678-9199-20-44. PMC 4197285. PMID 25320574.
- Geisbert TW, Jahrling PB (1995). "Differentiation of filoviruses by electron microscopy". Virus research 39 (2–3): 129–150. doi:10.1016/0168-1702(95)00080-1. PMID 8837880.
- Kühl A, Pöhlmann S (September 2012). "How Ebola virus counters the interferon system". Zoonoses Public Health 59 (Supplement 2): 116–31. doi:10.1111/j.1863-2378.2012.01454.x. PMID 22958256.
- Feldmann, H.; Geisbert, T. W.; Jahrling, P. B.; Klenk, H.-D.; Netesov, S. V.; Peters, C. J.; Sanchez, A.; Swanepoel, R.; Volchkov, V. E. (2005). "Family Filoviridae". In Fauquet, C. M.; Mayo, M. A.; Maniloff, J.; Desselberger, U.; Ball, L. A. Virus Taxonomy – Eighth Report of the International Committee on Taxonomy of Viruses. San Diego, US: Elsevier/Academic Press. pp. 645–653. ISBN 0-12-370200-3.
- Smith, Tara (2005). Ebola (Deadly Diseases and Epidemics). Chelsea House Publications. ISBN 0-7910-8505-8.
- Sullivan N, Yang ZY, Nabel GJ (2003). "Ebola Virus Pathogenesis: Implications for Vaccines and Therapies" (Free full text). Journal of Virology 77 (18): 9733–9737. doi:10.1128/JVI.77.18.9733-9737.2003. PMC 224575. PMID 12941881.
- Olejnik J, Ryabchikova E, Corley RB, Mühlberger E (August 2011). "Intracellular events and cell fate in filovirus infection". Viruses 3 (8): 1501–31. doi:10.3390/v3081501. PMC 3172725. PMID 21927676.
- Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW (September 2011). "Filoviral immune evasion mechanisms". Viruses 3 (9): 1634–49. doi:10.3390/v3091634. PMC 3187693. PMID 21994800.
- "Ebola Hemorrhagic Fever Diagnosis". CDC. 28 January 2014. Retrieved 3 August 2014.
- Grolla A, Lucht A, Dick D, Strong JE, Feldmann H (2005). "Laboratory diagnosis of Ebola and Marburg hemorrhagic fever". Bull Soc Pathol Exot 98 (3): 205–9. PMID 16267962.
- Kortepeter MG, Bausch DG, Bray M (November 2011). "Basic clinical and laboratory features of filoviral hemorrhagic fever". J Infect Dis 204 (Supplement 3): S810–6. doi:10.1093/infdis/jir299. PMID 21987756.
- Longo, DL; Kasper, DL; Jameson, JL; Fauci, AS; Hauser, SL; Loscalzo, J, eds. (2012). "Chapter 197". Harrison's Principles of Internal Medicine (18th ed.). McGraw-Hill. ISBN 0-07-174889-X.
- "Viral Hemorrhagic Fever". San Francisco Department of Public Health. Communicable Disease Control and Prevention. Retrieved 17 August 2014.
- Gear JH (1989). "Clinical aspects of African viral hemorrhagic fevers". Reviews of infectious diseases. 11 Suppl 4: S777–S782. doi:10.1093/clinids/11.supplement_4.s777. PMID 2665013.
- Gear JH, Ryan J, Rossouw E (1978). "A consideration of the diagnosis of dangerous infectious fevers in South Africa". South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 53 (7): 235–237. PMID 565951.
- Grolla A, Lucht A, Dick D, Strong JE, Feldmann H (2005). "Laboratory diagnosis of Ebola and Marburg hemorrhagic fever". Bulletin de la Societe de pathologie exotique (1990) 98 (3): 205–209. PMID 16267962.
- Bogomolov BP (1998). "Differential diagnosis of infectious diseases with hemorrhagic syndrome". Terapevticheskii arkhiv 70 (4): 63–68. PMID 9612907.
- "Ebola Hemorrhagic Fever Prevention". CDC. 31 July 2014. Retrieved 2 August 2014.
- "Guidance on Personal Protective Equipment To Be Used by Healthcare Workers During Management of Patients with Ebola Virus Disease in U.S. Hospitals, Including Procedures for Putting On (Donning) and Removing (Doffing)". cdc.gov. 20 October 2014. Retrieved 22 October 2014.
- C. J. Peters (December 1998). Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting. Centers for Disease Control and Prevention.
- Ebola medics 'better trained in Sierra Leone than Spain' The Telegraph, by Fiona Govan, 11 Oct. 2014
- This Is How Ebola Patients Are Equipping Their Homes Time magazine, by Alexandra Sifferlin, 9 October 2014
- Nossiter and Kanter (10 October 2014). "Doctors Without Borders Evolves as It Forms the Vanguard in Ebola Fight". The New York Times. Retrieved 12 October 2014.
- "Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-care Settings with Focus on Ebola". Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-care Settings with Focus on Ebola. WHO. August 2014. Retrieved 21 August 2014.
- "Ebolavirus - Pathogen Safety Data Sheets". Laboratory Biosafety and Biosecurity > Biosafety Programs and Resources > Pathogen Safety Data Sheets and Risk Assessment. Public Health Agency of Canada.
- "Ebola – 5 tips to avoid the deadly disease". Plan International. 6 September 2014.
- Rouquet P, Froment JM, Bermejo M, Kilbourn A, Karesh W, Reed P, Kumulungui B, Yaba P, Délicat A, Rollin PE, Leroy EM (Feb 2005). "Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001–2003" (Free full text). Emerging Infectious Diseases 11 (2): 283–290. doi:10.3201/eid1102.040533. ISSN 1080-6040. PMC 3320460. PMID 15752448.
- Centers for Disease Control and Prevention and World Health Organization (1998). Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting (PDF). Atlanta, Georgia, US: Centers for Disease Control and Prevention. Retrieved 8 February 2013.
- "Section 7: Use Safe Burial Practices". Information resources on Ebola virus disease. World Health Organization. 1 June 2014.
- Blaine Harden (24 December 2000). "Ebola's Shadow". The New York Times. Retrieved 12 October 2014.
- How anthropologists help medics fight Ebola in Guinea. Science and Development. Sept. 2014, accessdate 3 October 2014. http://www.scidev.net/global/cooperation/feature/anthropologists-medics-ebola-guinea.html
- "West Africa - Ebola virus disease Update: Travel and transport". International travel and health. World Health Organization.
- Sompayrac, Lauren (2002). How pathogenic viruses work (3. print. ed.). Boston: Jones and Bartlett Publishers. p. 87. ISBN 9780763720827.
- Alazard-Dany N, Ottmann Terrangle M, Volchkov V (2006). "[Ebola and Marburg viruses: the humans strike back]". Med Sci (Paris) (in French) 22 (4): 405–10. doi:10.1051/medsci/2006224405. PMID 16597410.
- Special Pathogens Branch CDC (14 January 2008). "Known Cases and Outbreaks of Ebola Hemorrhagic Fever". Center for Disease Control and Prevention. Retrieved 2 August 2008.
- Schultz, edited by Kristi Koenig, Carl (2009). Koenig and Schultz's disaster medicine : comprehensive principles and practices. Cambridge: Cambridge University Press. p. 209. ISBN 9780521873673.
- Lewis1, David (30 July 2014). "Liberia shuts schools, considers quarantine to curb Ebola". Reuters. Retrieved 3 August 2014.
- "Ohio, Texas schools close amid Ebola scare". USAToday. 16 Oct 2014. Retrieved 16 October 2014.
- "Ebola 2014 — New Challenges, New Global Response and Responsibility". NEJM. New England Journal of Medecine. Retrieved 15 September 2014.
- "What is Contact Tracing?". CDC. Centers for Disease Control. Retrieved 15 September 2014.
- Choi JH, Croyle MA (2013). "Emerging targets and novel approaches to Ebola virus prophylaxis and treatment". BioDrugs 27 (6): 565–83. doi:10.1007/s40259-013-0046-1. PMID 23813435.
- Clark DV, Jahrling PB, Lawler JV (2012). "Clinical management of filovirus-infected patients". Viruses 4 (9): 1668–86. doi:10.3390/v4091668. PMC 3499825. PMID 23170178.
- "FDA warns consumers about fraudulent Ebola treatment products". Retrieved 20 August 2014.
- "Inspections, Compliance, Enforcement, and Criminal Investigations". FDA. Retrieved 9 October 2014.
- C.M. Fauquet (2005). Virus taxonomy classification and nomenclature of viruses; 8th report of the International Committee on Taxonomy of Viruses. Oxford: Elsevier/Academic Press. p. 648. ISBN 9780080575483.
- "More or Less behind the stats Ebola". www.bbc.co.uk. BBC World Service. Retrieved 8 October 2014.
- "Who, What, Why: How many people infected with ebola die?". BBC News. 9 August 2014.
- "2014 Ebola Outbreak in West Africa - Case Counts". 2014 Ebola Outbreak in West Africa. CDC (Centers for Disease Control and Prevention). 2014.
- WHO (22 Oct 2014). "Ebola Response Roadmap Situation Report". who.int. Retrieved 22 Oct 2014.
- Peterson AT, Bauer JT, Mills JN (2004). "Ecologic and Geographic Distribution of Filovirus Disease". Emerging Infectious Diseases 10 (1): 40–47. doi:10.3201/eid1001.030125. PMC 3322747. PMID 15078595.
- "Ebola haemorrhagic fever in Sudan, 1976" (pdf).
- Feldmann H, Geisbert TW (2011). "Ebola haemorrhagic fever". The Lancet 377 (9768): 849–862. doi:10.1016/S0140-6736(10)60667-8. PMID 21084112.
- Hewlett, Barry; Hewlett, Bonnie (2007). Ebola, Culture and Politics: The Anthropology of an Emerging Disease. Cengage Learning. p. 103. Retrieved 31 July 2014.
- Feldmann H, Jones S, Klenk HD, Schnittler HJ (August 2003). "Ebola virus: from discovery to vaccine". Nature Reviews. Immunology 3 (8): 677–85. doi:10.1038/nri1154. PMID 12974482.
- "Ebola haemorrhagic fever in Zaire, 1976". Bull. World Health Organ. 56 (2): 271–93. 1978. PMC 2395567. PMID 307456.
- Stimola, Aubrey. Ebola, Rosen Publ. (2011) pp. 31, 52
- Piot, Peter. No Time to Lose: A Life in Pursuit of Deadly Viruses, W. W. Norton (2012) pp. 30, 90
- Bardi, Jason Socrates. "Death Called a River". The Scripps Research Institute. Retrieved 9 October 2014.
- Feldmann H, Geisbert TW (March 2011). "Ebola haemorrhagic fever". Lancet 377 (9768): 849–62. doi:10.1016/S0140-6736(10)60667-8. PMC 3406178. PMID 21084112.
- Preston, Richard (20 July 1995). The Hot Zone. Anchor Books (Random House). p. 117. "Karl Johnson named it Ebola"
- Bredow, Rafaela von; Hackenbroch, Veronika (4 October 2014). "'In 1976 I Discovered Ebola – Now I Fear an Unimaginable Tragedy'". The Observer. Guardian Media Group.
- King JW (2 April 2008). "Ebola Virus". eMedicine. WebMd. Retrieved 6 October 2008.
- "Mystery DR Congo fever kills 100". BBC News. 31 August 2007. Retrieved 25 February 2008.
- Formenty P, Libama F, Epelboin A, Allarangar Y, Leroy E, Moudzeo H, Tarangonia P, Molamou A, Lenzi M, Ait-Ikhlef K, Hewlett B, Roth C, Grein T (2003). "[Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?]". Med Trop (Mars) (in French) 63 (3): 291–5. PMID 14579469.
- "Russian Scientist Dies in Ebola Accident at Former Weapons Lab". The New York Times. Retrieved 12 October 2014.
- "Ebola Outbreak Confirmed in Congo". NewScientist.com. 11 September 2007. Retrieved 25 February 2008.
- Ebola outbreak in Congo. CDC news. 12 September 2007. Retrieved 31 May 2009.
- "Uganda: Deadly Ebola Outbreak Confirmed – UN". UN News Service. 30 November 2007. Retrieved 25 February 2008.
- "DRC Confirms Ebola Outbreak". Voanews.com. Retrieved 15 April 2013.
- "WHO | Ebola outbreak in Democratic Republic of Congo". Who.int. 17 August 2012. Retrieved 15 April 2013.
- "WHO | Ebola outbreak in Democratic Republic of Congo – update". Who.int. 21 August 2012. Retrieved 15 April 2013.
- Castillo M (2012). "Ebola virus claims 31 lives in Democratic Republic of the Congo". United States: CBS News. Retrieved 14 September 2012.
- "Guidelines for Evaluation of US Patients Suspected of Having Ebola Virus Disease". CDC. 1 August 2014. Retrieved 5 August 2014.
- Grady, Denise; Sheri Fink (9 August 2014). "Tracing Ebola’s Breakout to an African 2-Year-Old". The New York Times. ISSN 0362-4331. Retrieved 10 August 2014.
- "The first cases of this Ebola outbreak traced by WHO" (png). who.int. WHO. 2014.
- "WHO raises global alarm over Ebola outbreak". CBS. Retrieved 2 August 2014.
- "In Liberia's Ebola-Stricken Villages, Residents Face 'Stark' Choices". n Liberia's Ebola-Stricken Villages, Residents Face 'Stark' Choices. Common Dreams. 18 August 2014. Retrieved 20 August 2014.
- "Disease outbreak news – Ebola virus disease, West Africa – update 28 August 2014". Epidemic & Pandemic Alert and Response (EPR) – Outbreak News (WHO). Retrieved 28 August 2014.
- "Ebola virus disease update, West Africa – update 28 August 2014". Epidemic & Pandemic Alert and Response (EPR) – Outbreak News (WHO). Retrieved 28 August 2014.
- "Senegalese minister of health confirms 1st case of Ebola virus in the West African country". Washington Post. 29 August 2014. Retrieved 29 August 2014.
- "First case of Ebola virus is confirmed in Senegal". ITV. 29 August 2014. Retrieved 29 August 2014.
- Staff (30 September 2014). "CDC and Texas Health Department Confirm First Ebola Case Diagnosed in the U.S.". CDC. Retrieved 30 September 2014.
- Bustillo, Miguel; Campoy, Ann; Hinshaw, Drew. "Dallas Ebola Patient Dies". The Wall Street Journal Online. Retrieved 8 October 2014.
- statement (26 September 2014). "http://www.who.int/mediacentre/news/ebola/26-september-2014/en/". WHO. Retrieved 28 September 2014.
- WHO: EBOLA RESPONSE ROADMAP UPDATE-8 September 2014, WHO
- "Unprecedented number of medical staff infected with Ebola". WHO. 25 August 2014. Retrieved 29 August 2014.
- WHO: Ebola Response Roadmap Situation Report - 1 October 2014
- "Ebola Facts: How Many Ebola Patients Are Being Treated Outside of West Africa?".
- "Second US Ebola diagnosis 'deeply concerning', admits CDC chief".
- "Thomas Eric Duncan: First Ebola death in U.S.".
- Fernandez, Manny (12 October 2014). "Texas Health Worker Tests Positive for Ebola". New York Times. Retrieved 12 October 2014.
- "Ebola in Texas: Second Health Care Worker Tests Positive".
- Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K (2002). "Hemorrhagic fever viruses as biological weapons: medical and public health management". Journal of the American Medical Association 287 (18): 2391–405. doi:10.1001/jama.287.18.2391. PMID 11988060.
- Salvaggio MR, Baddley JW (2004). "Other viral bioweapons: Ebola and Marburg hemorrhagic fever". Dermatologic clinics 22 (3): 291–302, vi. doi:10.1016/j.det.2004.03.003. PMID 15207310.
- Zubray, Geoffrey (2013). Agents of Bioterrorism: Pathogens and Their Weaponization. New York, NY, USA: Columbia University Press. pp. 73–74. ISBN 9780231518130.
- (1) Preston, Richard (1995). The Hot Zone, A Terrifying True Story. Anchor Books. ISBN 0-385-47956-5. OCLC 32052009. At Google Books.
(2) "Best Sellers: June 4, 1995". The New York Times Book Review (New York: The New York Times). 4 June 1995. Retrieved 10 September 2014.
(3) "About The Hot Zone". Random House. Retrieved 10 September 2014.
- (1) Close, William T. (1995). Ebola: A Documentary Novel of Its First Explosion. New York: Ivy Books. ISBN 0804114323. OCLC 32753758. At Google Books.
(2) Grove, Ryan (2 June 2006). "More about the people than the virus". Review of Close, William T., Ebola: A Documentary Novel of Its First Explosion. Amazon.com. Retrieved 17 September 2014.
(3) Close, William T. (2002). Ebola: Through the Eyes of the People. Marbleton, Wyoming: Meadowlark Springs Productions. ISBN 0970337116. OCLC 49193962. At Google Books.
(4) Pink, Brenda (24 June 2008). "A fascinating perspective". Review of Close, William T., Ebola: Through the Eyes of the People. Amazon.com. Retrieved 17 September 2014.
- (1) Clancy, Tom (1996). Executive Orders. New York: Putnam. ISBN 0399142185. OCLC 34878804. At Google Books.
(2) Line, Matt; Jeremy; Dan. "Executive Orders book reviews". AllReaders.com. Archived from the original on 1 August 2014. Retrieved 10 September 2014.
(3) Stone, Oliver (2 September 1996). "Who's That in the Oval Office?". Books News & Reviews. The New York Times Company. Archived from the original on 10 April 2009. Retrieved 10 September 2014.
- Choi JH, Croyle MA (2013). "Emerging targets and novel approaches to Ebola virus prophylaxis and treatment". BioDrugs 27 (6): 565–83. doi:10.1007/s40259-013-0046-1. PMID 23813435.
- Ebola 'kills over 5,000 gorillas'. BBC. 8 December 2006. Retrieved 31 May 2009.
- Leroy EM, Rouquet P, Formenty P, Souquière S, Kilbourne A, Froment JM, Bermejo M, Smit S, Karesh W, Swanepoel R, Zaki SR, Rollin PE (2004). "Multiple Ebola virus transmission events and rapid decline of central African wildlife". Science 303 (5656): 387–390. Bibcode:2004Sci...303..387L. doi:10.1126/science.1092528. PMID 14726594.
- Formenty P, Boesch C, Wyers M, Steiner C, Donati F, Dind F, Walker F, Le Guenno B (1999). "Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d'Ivoire". The Journal of infectious diseases. 179. Suppl 1 (s1): S120–S126. doi:10.1086/514296. PMID 9988175.
- Preston, Richard (1994). The Hot Zone. New York: Random House. p. 300. ISBN 978-0679437840.
- McCormick & Fisher-Hoch 1999, pp. 277–279
- Waterman, Tara (1999). Ebola Reston Outbreaks. Stanford University. Retrieved 2 August 2008.
- McCormick & Fisher-Hoch 1999, pp. 298–299
- McCormick & Fisher-Hoch 1999, p. 300
- Weingartl HM, Nfon C, Kobinger G (2013). "Review of Ebola virus infections in domestic animals". Dev Biol (Basel) 135: 211–8. doi:10.1159/000178495. PMID 23689899.
- McNeil Jr, Donald G. (24 January 2009). "Pig-to-Human Ebola Case Suspected in Philippines". New York Times. Retrieved 26 January 2009.
- Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G (2012). "Transmission of Ebola virus from pigs to non-human primates". Sci Rep 2: 811. doi:10.1038/srep00811. PMC 3498927. PMID 23155478.
- Allela L, Boury O, Pouillot R, Délicat A, Yaba P, Kumulungui B, Rouquet P, Gonzalez JP, Leroy EM (2005). "Ebola virus antibody prevalence in dogs and human risk". Emerging Infect. Dis. 11 (3): 385–90. doi:10.3201/eid1103.040981. PMC 3298261. PMID 15757552.
- Briggs H. "BBC News - Ebola: Experimental drugs and vaccines". BBC News. Retrieved 8 August 2014.
- Gaffney A (7 August 2014). "Regulatory Explainer: What You Need to Know About the Regulation of Ebola Treatments". Regulatory Affairs Professionals Society (RAPS).
- "Ethical considerations for use of unregistered interventions for Ebola virus disease (EVD)". WHO. Retrieved 20 August 2014.
- Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Res. 105: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
- "French nurse cured of Ebola contracted in Liberia". MSN. Retrieved 7 October 2014.
- "BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks'. David Kroll, Forbes Magazine. 29 August 2014". Forbes. 29 August 2014. Retrieved 5 October 2014.
- "DURHAM: BioCryst receives additional funding for Ebola drug - WNCN: News, Weather". WNCN. 18 September 2014. Retrieved 5 October 2014.
- "Chimerix gets FDA approval to test drug for Ebola.". Associated Press. 17 October 2014.
- "Chimerix Announces Emergency Investigational New Drug Applications for Brincidofovir Authorized by FDA for Patients With Ebola Virus Disease". Retrieved 7 October 2014.
- Perrone, Matthew (6 October 2014). "Experimental Drug Provided to Dallas Ebola Patient". ABC. AP. Retrieved 6 October 2014.
- "Doctor treats Ebola with HIV drug in Liberia -- seemingly successfully. Elizabeth Cohen, CNN news. 29 September 2014". CNN. 27 September 2014. Retrieved 7 October 2014.
- "A Liberian doctor is using HIV drugs to treat Ebola victims. The NIH is intrigued. Elahe Izadi, Washington Post. 2 October 2014". Washington Post. Retrieved 7 October 2014.
- Ebola virus drug approved on mainland for emergency use only. Zhuang Pinghui, South China Morning Post, 01 September 2014
- China military-linked firm eyes quick approval of drug to cure Ebola. Adam Jourdan, Yahoo News, 14 October 2014
- Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG, McMahon JB, Huggins J, O'Keefe BR (2014). "The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus". Antiviral Research. doi:10.1016/j.antiviral.2014.09.012. PMID 25265598.
- Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, Montefiori DC, Vojdani F, McCormick AA, O'Keefe BR, Palmer KE (2014). "Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models". Antimicrobial Agents and Chemotherapy 58 (1): 120–7. doi:10.1128/AAC.01407-13. PMC 3910741. PMID 24145548.
- De Clercq E (2013). "A Cutting-Edge View on the Current State of Antiviral Drug Development". Medicinal Research Reviews: n/a. doi:10.1002/med.21281. PMID 23495004.
- Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS (2014). "Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay". Journal of Virology 88 (8): 4353–65. doi:10.1128/JVI.03050-13. PMC 3993759. PMID 24501399.
- Mudhasani R, Kota KP, Retterer C, Tran JP, Whitehouse CA, Bavari S (2014). "High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses". PLoS Neglected Tropical Diseases 8 (8): e3095. doi:10.1371/journal.pntd.0003095. PMC 4140764. PMID 25144302.
- Johnson JC, Martinez O, Honko AN, Hensley LE, Olinger GG, Basler CF (2014). "Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells". Antiviral Research 107: 102–9. doi:10.1016/j.antiviral.2014.04.014. PMC 4103912. PMID 24815087.
- Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I (29 May 2010). "Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study". The Lancet 375 (9729): 1896–1905. doi:10.1016/S0140-6736(10)60357-1. PMID 20511019.
- Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S (September 2010). "Advanced antisense therapies for postexposure protection against lethal filovirus infections". Nature Medicine 16 (9): 991–994. doi:10.1038/nm.2202. PMID 20729866.
- Pollack, Andrew (7 August 2014). "Second drug is allowed for treatment of Ebola". The New York Times. Retrieved 8 August 2014.
- Helen Branswell (3 August 2014). "Nancy Writebol, U.S. missionary, didn't get TKM-Ebola drug, Tekmira says". CBC News. Canadian Press.
- Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E (25 August 2014). "Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single ascending dose studies". Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.03442-14. PMID 25155593.
- Kroll, David (26 August 2014). "How will we know if the Ebola drugs worked?". Forbes. Retrieved 1 October 2014.
- Nathan Seppa (29 August 2014). "ZMapp drug fully protects monkeys against Ebola virus". Science News (Society for Science & the Public). Retrieved 1 October 2014.
- Thai researchers claim breakthrough in Ebola treatment. Ron Corben, Voice of America News, 3 October 2014
- Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG (2013). "FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection". Sci Transl Med 5 (190): 190ra79. doi:10.1126/scitranslmed.3005471. PMC 3955358. PMID 23785035. Lay summary – Healthline Networks, Inc.
- Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pöhlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T (2014). "The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry". J. Antimicrob. Chemother. 69 (8): 2123–31. doi:10.1093/jac/dku091. PMID 24710028.
- Tan DX, Korkmaz A, Reiter RJ, Manchester LC (27 September 2014). "Ebola virus disease: Potential use of melatonin as a treatment.". Journal of pineal research. PMID 25262626.
- "Blood transfusion named as priority treatment for Ebola". Nature. Retrieved 11 September 2014.
- "Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease Empirical treatment during outbreaks". WHO. Retrieved 4 October 2014.
- "Statement on the WHO Consultation on potential Ebola therapies and vaccines". WHO. 5 September 2014. Retrieved 1 October 2014.
- Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ (1999). "Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee". J. Infect. Dis. 179 Suppl 1: S18–23. doi:10.1086/514298. PMID 9988160.
- Saphire EO (2013). "An update on the use of antibodies against the filoviruses". Immunotherapy 5 (11): 1221–33. doi:10.2217/imt.13.124. PMID 24188676.
- Gulland A (8 September 2014). "First Ebola treatment is approved by WHO". BMJ 349 (sep08 7): g5539–g5539. doi:10.1136/bmj.g5539. PMID 25200068.
- Richardson JS, Dekker JD, Croyle MA, Kobinger GP (June 2010). "Recent advances in Ebolavirus vaccine development". Human Vaccines (open access) 6 (6): 439–49. doi:10.4161/hv.6.6.11097. PMID 20671437.
- "2014 Ebola Outbreakin West Africa". Retrieved Oct 2014.
- Alison P. Galvani with three others (21 August 2014). "Ebola Vaccination: If Not Now, When?". Annals of Internal Medicine. doi:10.7326/M14-1904.
- Hugues Fausther-Bovendo with two others (2012). "Ebolavirus vaccines for humans and apes". Current Opinion in Virology 2 (3): 324–329. doi:10.1016/j.coviro.2012.04.003.
- Vaccine Research Center, NIAID (29 September 2014). "Ebola Vaccine Clinical Development Overview (presentation)". Retrieved 21 Oct 2014.
- "Canadian-made Ebola vaccine to start clinical trials in healthy humans". Globe and Mail. Oct 13, 2014. Retrieved 13 October 2014.
- "Ebola outbreak: 1st human trials of Canadian vaccine start in U.S.". CBC News. Oct 13, 2014.
- "Canadian Ebola vaccine license holder moving ahead with safety trials". Canadian Press. Oct 8, 2014. Retrieved 13 October 2014.
- "A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults". US NIAID. Oct 9, 2014. Retrieved 13 October 2014.
- Hannah Thibedeau (Oct 19, 2014). "Ebola vaccine to be sent to WHO on Monday for clinical trials". CBC News. Retrieved Oct 21, 2014.
- Ebola crisis: Vaccine 'too late' for outbreak. BBC News, 17 October 2014
- 70-90% efficiency: Russia to send Ebola vaccine to W. Africa in 2 months. RT.com 13 October 2014
- Russian Scientists Develop New Vaccine to Fight Ebola Virus. The Moscow Times, 27 August 2014
- Klenk, Hans-Dieter (January 1999). Marburg and Ebola Viruses (Current Topics in Microbiology and Immunology). Berlin: Springer-Verlag Telos. ISBN 978-3-540-64729-4.
- Klenk, Hans-Dieter; Feldmann, Heinz (2004). Ebola and Marburg viruses: molecular and cellular biology (Limited preview). Wymondham, Norfolk, UK: Horizon Bioscience. ISBN 978-0-9545232-3-7.
- Kuhn, Jens H. (2008). Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies. Archives of Virology Supplement, vol. 20 (Limited preview). Vienna: SpringerWienNewYork. ISBN 978-3-211-20670-6.
- McCormick, Joseph; Fisher-Hoch, Susan (June 1999) . Level 4: Virus Hunters of the CDC (Limited preview). Horvitz, Leslie Alan (Updated [3rd] ed.). Barnes & Noble. ISBN 978-0-7607-1208-5.
- Pattyn, S. R. (1978). Ebola Virus Haemorrhagic Fever (Full free text) (1st ed.). Amsterdam: Elsevier/North-Holland Biomedical Press. ISBN 0-444-80060-3.
- Ryabchikova, Elena I.; Price, Barbara B. (2004). Ebola and Marburg Viruses: A View of Infection Using Electron Microscopy. Columbus, Ohio: Battelle Press. ISBN 978-1-57477-131-2.
|Find more about Ebola virus disease at Wikipedia's sister projects|
|Definitions from Wiktionary|
|Media from Commons|
|News stories from Wikinews|
|Quotations from Wikiquote|
|Database entry Q51993 on Wikidata|
- Ebola virus disease at DMOZ
- CDC: Ebola hemorrhagic fever – Centers for Disease Control and Prevention, Special Pathogens Branch
- WHO: Ebola haemorrhagic fever – World Health Organization, Global Alert and Response
- Google Map of Ebola Outbreaks
- WHO recommended infection control measures